Literature DB >> 19322916

Down-regulation of extracellular signal-regulated kinase 1/2 activity in P-glycoprotein-mediated multidrug resistant hepatocellular carcinoma cells.

Feng Yan1, Xiao-Min Wang, Chao Pan, Quan-Ming Ma.   

Abstract

AIM: To study the expression and phosphorylation of extracellular signal-regulated kinase (ERK) 1 and ERK2 in multidrug resistant (MDR) hepatocellular carcinoma (HCC) cells.
METHODS: MDR HCC cell lines, HepG2/adriamycin (ADM) and SMMC7721/ADM, were developed by exposing parental cells to stepwise increasing concentrations of ADM. MTT assay was used to determine drug sensitivity. Flow cytometry was employed to analyze cell cycle distribution and measure cell P-glycoprotein (P-gp) and multidrug resistant protein 1 (MRP1) expression levels. ERK1 and ERK2 mRNA expression levels were measured by quantitative real-time PCR (QRT-PCR). Expression and phosphorylation of ERK1 and ERK2 were analyzed by Western blot.
RESULTS: MTT assay showed that HepG2/ADM and SMMC7721/ADM were resistant not only to ADM, but also to multiple anticancer drugs. The P-gp expression was over 10-fold higher in HepG2/ADM cells than in HepG2 cells (8.92% +/- 0.22% vs 0.88% +/- 0.05%, P < 0.001) and over 4-fold higher in SMMC7721/ADM cells than in SMMC7721 cells (7.37% +/- 0.26% vs 1.74% +/- 0.25%, P < 0.001). However, the MRP1 expression was not significantly higher in HepG2/ADM and SMMC7721/ADM cells than in parental cells. In addition, the percentage of MDR HepG2/ADM and SMMC7721/ADM cells was significantly decreased in the G0/G1 phase and increased in the the S phase or G2/M phase. QRT-PCR analysis demonstrated that the ERK1 and ERK2 mRNA expression increased apparently in HepG2/ADM cells and decreased significantly in SMMC7721/ADM cells. Compared with the expression of parental cells, ERK1 and ERK2 protein expressions were markedly decreased in SMMC7721/ADM cells. However, ERK2 protein expression was markedly increased while ERK1 protein expression had no significant change in HepG2/ADM cells. Phosphorylation of ERK1 and ERK2 was markedly decreased in both HepG2/ADM and SMMC7721/ADM MDR cells.
CONCLUSION: ERK1 and ERK2 activities are down-regulated in P-gp-mediated MDR HCC cells. ERK1 or ERK2 might be a potential drug target for circumventing MDR HCC cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19322916      PMCID: PMC2665138          DOI: 10.3748/wjg.15.1443

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

1.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

Review 2.  Cellular mechanisms of multidrug resistance of tumor cells.

Authors:  A A Stavrovskaya
Journal:  Biochemistry (Mosc)       Date:  2000-01       Impact factor: 2.487

Review 3.  Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases.

Authors:  Gary L Johnson; Razvan Lapadat
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

4.  Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins.

Authors:  D W Shen; C Cardarelli; J Hwang; M Cornwell; N Richert; S Ishii; I Pastan; M M Gottesman
Journal:  J Biol Chem       Date:  1986-06-15       Impact factor: 5.157

5.  Reversal effect of specific inhibitors of extracellular-signal regulated protein kinase pathway on P-glycoprotein mediated vincristine resistance of L1210 cells.

Authors:  J Kisucká; M Barancík; V Bohácová; A Breier
Journal:  Gen Physiol Biophys       Date:  2001-12       Impact factor: 1.512

6.  Reversal of P-glycoprotein-mediated multidrug resistance in human sarcoma MES-SA/Dx-5 cells by nonsteroidal anti-inflammatory drugs.

Authors:  Antonio Angelini; Manuela Iezzi; Concetta Di Febbo; Carmine Di Ilio; Franco Cuccurullo; Ettore Porreca
Journal:  Oncol Rep       Date:  2008-10       Impact factor: 3.906

7.  Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis.

Authors:  Yanping Hu; Marcel Bally; Wieslawa H Dragowska; Lawrence Mayer
Journal:  Mol Cancer Ther       Date:  2003-07       Impact factor: 6.261

8.  High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells.

Authors:  K Mehta
Journal:  Int J Cancer       Date:  1994-08-01       Impact factor: 7.396

9.  A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene.

Authors:  M A Barrand; A C Heppell-Parton; K A Wright; P H Rabbitts; P R Twentyman
Journal:  J Natl Cancer Inst       Date:  1994-01-19       Impact factor: 13.506

Review 10.  Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.

Authors:  Giorgio Minotti; Pierantonio Menna; Emanuela Salvatorelli; Gaetano Cairo; Luca Gianni
Journal:  Pharmacol Rev       Date:  2004-06       Impact factor: 25.468

View more
  8 in total

1.  MAPK1 of Leishmania donovani modulates antimony susceptibility by downregulating P-glycoprotein efflux pumps.

Authors:  Mansi Garg; Neena Goyal
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

Review 2.  Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma.

Authors:  Amir Mehdizadeh; Mohammad Hossein Somi; Masoud Darabi; Mortaza Jabbarpour-Bonyadi
Journal:  Mol Biol Rep       Date:  2016-01-14       Impact factor: 2.316

3.  Chemosensitization of HepG2 cells by suppression of NF-κB/p65 gene transcription with specific-siRNA.

Authors:  Yun Shi; Si-Ye Wang; Min Yao; Wen-Li Sai; Wei Wu; Jun-Ling Yang; Yin Cai; Wen-Jie Zheng; Deng-Fu Yao
Journal:  World J Gastroenterol       Date:  2015-12-07       Impact factor: 5.742

4.  Expression and Functions of Formyl Peptide Receptor 1 in Drug-Resistant Bladder Cancer.

Authors:  Xue Jiang; Ting Lei; Man Zhang
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

5.  A 4-Phenoxyphenol Derivative Exerts Inhibitory Effects on Human Hepatocellular Carcinoma Cells through Regulating Autophagy and Apoptosis Accompanied by Downregulating α-Tubulin Expression.

Authors:  Wen-Tsan Chang; Wangta Liu; Yi-Han Chiu; Bing-Hung Chen; Shih-Chang Chuang; Yen-Chun Chen; Yun-Tzh Hsu; Mei-Jei Lu; Shean-Jaw Chiou; Chon-Kit Chou; Chien-Chih Chiu
Journal:  Molecules       Date:  2017-05-21       Impact factor: 4.411

6.  Ferroptosis-Related Hub Genes in Hepatocellular Carcinoma: Prognostic Signature, Immune-Related, and Drug Resistance Analysis.

Authors:  Wei Wang; Fan Pan; Xinrong Lin; Jiakai Yuan; Chunyu Tao; Rui Wang
Journal:  Front Genet       Date:  2022-07-22       Impact factor: 4.772

7.  Downregulation of δ opioid receptor by RNA interference enhances the sensitivity of BEL/FU drug‑resistant human hepatocellular carcinoma cells to 5‑FU.

Authors:  Bo Tang; Zhigao Hu; Yang Li; Shengguang Yuan; Zhenran Wang; Shuiping Yu; Songqing He
Journal:  Mol Med Rep       Date:  2015-11-06       Impact factor: 2.952

8.  Involvement of CUL4A in regulation of multidrug resistance to P-gp substrate drugs in breast cancer cells.

Authors:  Yunshan Wang; Guangxin Ma; Qin Wang; Mingxin Wen; Yangyang Xu; Xiuquan He; Pengju Zhang; Yuli Wang; Taomei Yang; Panpan Zhan; Guangwei Wei
Journal:  Molecules       Date:  2013-12-24       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.